CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Standard BioTools Inc - LAB CFD

    2.5537
    0.79%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.0226
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Standard BioTools Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.5337
    Open* 2.5837
    1-Year Change* 48.77%
    Day's Range* 2.5537 - 2.6337
    52 wk Range 1.46-3.16
    Average Volume (10 days) 3.46M
    Average Volume (3 months) 23.30M
    Market Cap 662.87M
    P/E Ratio -100.00K
    Shares Outstanding 289.46M
    Revenue 105.17M
    EPS -0.96
    Dividend (Yield %) N/A
    Beta 1.67
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 22, 2024 2.5337 -0.0300 -1.17% 2.5637 2.5837 2.5037
    Apr 19, 2024 2.5137 0.0200 0.80% 2.4937 2.5837 2.4737
    Apr 18, 2024 2.5237 -0.0700 -2.70% 2.5937 2.5937 2.5037
    Apr 17, 2024 2.6037 -0.1600 -5.79% 2.7637 2.7737 2.5837
    Apr 16, 2024 2.7037 -0.0800 -2.87% 2.7837 2.8237 2.6737
    Apr 15, 2024 2.7637 -0.0100 -0.36% 2.7737 2.8437 2.7037
    Apr 12, 2024 2.7637 -0.1300 -4.49% 2.8937 2.9337 2.6937
    Apr 11, 2024 2.8937 0.0600 2.12% 2.8337 2.9237 2.8137
    Apr 10, 2024 2.8237 -0.0600 -2.08% 2.8837 2.9137 2.7937
    Apr 9, 2024 2.9137 0.0700 2.46% 2.8437 3.0237 2.8437
    Apr 8, 2024 2.8637 0.1400 5.14% 2.7237 2.9337 2.7137
    Apr 5, 2024 2.7337 0.1200 4.59% 2.6137 2.7437 2.5837
    Apr 4, 2024 2.6337 -0.1900 -6.73% 2.8237 2.9137 2.5937
    Apr 3, 2024 2.6537 0.0600 2.31% 2.5937 2.7037 2.5937
    Apr 2, 2024 2.6237 -0.0200 -0.76% 2.6437 2.7437 2.6037
    Apr 1, 2024 2.7037 0.0200 0.75% 2.6837 2.7837 2.6137
    Mar 28, 2024 2.7037 0.0200 0.75% 2.6837 2.7637 2.6637
    Mar 27, 2024 2.6837 0.0500 1.90% 2.6337 2.7237 2.6237
    Mar 26, 2024 2.6337 -0.0300 -1.13% 2.6637 2.7137 2.6237
    Mar 25, 2024 2.6837 0.0400 1.51% 2.6437 2.7637 2.6437

    Standard BioTools Inc Events

    Time (UTC) Country Event
    Tuesday, May 7, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 Standard BioTools Inc Earnings Release
    Q1 2024 Standard BioTools Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, June 13, 2024

    Time (UTC)

    15:30

    Country

    US

    Event

    Standard BioTools Inc Annual Shareholders Meeting
    Standard BioTools Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Tuesday, August 6, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2024 Standard BioTools Inc Earnings Release
    Q2 2024 Standard BioTools Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 97.948 130.581 138.144 117.243 112.964
    Revenue 97.948 130.581 138.144 117.243 112.964
    Cost of Revenue, Total 60.897 61.208 54.818 52.964 51.315
    Gross Profit 37.051 69.373 83.326 64.279 61.649
    Total Operating Expense 214.153 198.049 189.18 181.102 161.128
    Selling/General/Admin. Expenses, Total 114.758 98.888 97.901 84.478 79.783
    Research & Development 38.498 37.944 36.461 31.64 30.03
    Unusual Expense (Income) 0.009 0 12.02
    Operating Income -116.205 -67.468 -51.036 -63.859 -48.164
    Interest Income (Expense), Net Non-Operating -64.412 -3.823 -3.572 -4.279 -13.893
    Other, Net -12.311 7.631 0.507 1.433 0.637
    Net Income Before Taxes -192.928 -63.66 -54.101 -66.705 -61.42
    Net Income After Taxes -190.098 -59.237 -53.02 -64.79 -59.013
    Net Income Before Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
    Net Income -190.098 -59.237 -53.02 -64.79 -59.013
    Income Available to Common Excl. Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
    Income Available to Common Incl. Extra. Items -190.098 -59.237 -53.02 -64.79 -59.013
    Dilution Adjustment
    Diluted Net Income -190.098 -59.237 -53.02 -64.79 -59.013
    Diluted Weighted Average Shares 78.305 75.786 72.044 66.779 39.652
    Diluted EPS Excluding Extraordinary Items -2.42766 -0.78164 -0.73594 -0.97022 -1.48827
    Diluted Normalized EPS -2.42766 -0.78156 -0.73594 -0.85322 -1.48827
    Total Extraordinary Items 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 27.666 25.119 27.021 25.646 18.777
    Revenue 27.666 25.119 27.021 25.646 18.777
    Cost of Revenue, Total 14.064 12.782 15.854 16.426 14.35
    Gross Profit 13.602 12.337 11.167 9.22 4.427
    Total Operating Expense 45.115 41.712 48.133 54.673 57.34
    Selling/General/Admin. Expenses, Total 22.6 21.295 23.902 29.597 30.084
    Research & Development 6.184 6.485 8.377 8.65 9.106
    Operating Income -17.449 -16.593 -21.112 -29.027 -38.563
    Interest Income (Expense), Net Non-Operating -1.129 -1.117 -1.19 -1.049 -23.351
    Other, Net 1.839 1.13 1.527 -0.063 -3.238
    Net Income Before Taxes -16.739 -16.58 -20.775 -30.139 -65.152
    Net Income After Taxes -17.04 -16.843 -20.845 -29.426 -63.539
    Net Income Before Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
    Net Income -17.04 -16.843 -20.845 -29.426 -63.539
    Income Available to Common Excl. Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
    Income Available to Common Incl. Extra. Items -17.04 -16.843 -20.845 -29.426 -63.539
    Diluted Net Income -17.04 -16.843 -20.845 -29.426 -63.539
    Diluted Weighted Average Shares 78.669 78.771 79.448 78.897 77.821
    Diluted EPS Excluding Extraordinary Items -0.2166 -0.21382 -0.26237 -0.37297 -0.81648
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -0.19787 -0.20433 -0.26237 -0.37297 -0.78474
    Unusual Expense (Income) 2.267 1.15 3.8
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 208.815 72.066 117.663 96.096 127.106
    Cash and Short Term Investments 165.784 28.451 68.52 58.639 95.401
    Cash 47.818 16.614 17.685
    Cash & Equivalents 81.309 28.451 20.702 5.047 77.716
    Short Term Investments 84.475 0 36.978 0
    Total Receivables, Net 17.28 18.32 25.423 18.981 16.651
    Accounts Receivable - Trade, Net 17.28 18.32 25.423 18.981 16.651
    Total Inventory 21.473 20.825 19.689 13.884 13.003
    Prepaid Expenses 3.263 3.454 4.031 4.592 2.051
    Total Assets 390.31 275.214 324.757 264.812 303.647
    Property/Plant/Equipment, Total - Net 59.535 65.153 55.645 12.916 8.825
    Property/Plant/Equipment, Total - Gross 98.995 98.954 83.42 39.668 31.68
    Accumulated Depreciation, Total -39.46 -33.801 -27.775 -26.752 -22.855
    Goodwill, Net 106.251 106.379 106.563 104.108 104.108
    Intangibles, Net 13.178 29.184 42.224 49.132 57.4
    Long Term Investments
    Other Long Term Assets, Total 2.531 2.432 2.662 2.56 6.208
    Total Current Liabilities 43.443 49.568 54.249 32.821 37.582
    Accounts Payable 7.914 10.602 9.22 6.51 4.027
    Accrued Expenses 19.01 16.646 31.554 14.508 22.091
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 14.436 15.482 13.475 11.803 11.464
    Total Liabilities 160.524 180.618 185.707 111.2 231.531
    Total Long Term Debt 62.809 64.209 54.224 53.821 172.058
    Long Term Debt 62.809 64.209 54.224 53.821 172.058
    Deferred Income Tax 1.055 4.329 8.697 11.494 13.714
    Other Liabilities, Total 53.217 62.512 68.537 13.064 8.177
    Total Equity 229.786 94.596 139.05 153.612 72.116
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.08 0.077 0.075 0.07 0.049
    Additional Paid-In Capital 847.008 831.424 815.624 777.765 631.605
    Retained Earnings (Accumulated Deficit) -926.096 -735.998 -676.761 -623.641 -558.851
    Other Equity, Total -1.394 -0.907 0.112 -0.618 -0.687
    Total Liabilities & Shareholders’ Equity 390.31 275.214 324.757 264.812 303.647
    Total Common Shares Outstanding 79.482 76.919 74.543 69.956 49.338
    Unrealized Gain (Loss) -0.502 0 0.036
    Other Current Assets, Total 1.015 1.016
    Current Port. of LT Debt/Capital Leases 2.083 6.838
    Redeemable Preferred Stock 311.253
    Treasury Stock - Common -0.563
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 170.741 183.07 194.928 208.815 229.017
    Cash and Short Term Investments 128.85 142.304 154.537 165.784 185.168
    Cash & Equivalents 79.655 142.304 113.663 81.309 60.2
    Total Receivables, Net 16.56 15.119 14.504 17.28 17.294
    Accounts Receivable - Trade, Net 16.56 15.119 14.504 17.28 17.294
    Total Inventory 21.927 22.08 22.513 21.473 21.946
    Prepaid Expenses 3.404 3.567 3.374 3.263 3.594
    Other Current Assets, Total 1.015 1.015
    Total Assets 339.285 355.827 371.654 390.31 414.915
    Property/Plant/Equipment, Total - Net 55.729 56.716 57.976 59.535 61.31
    Property/Plant/Equipment, Total - Gross 89.37 88.754 99.541 98.995 98.885
    Accumulated Depreciation, Total -33.641 -32.038 -41.565 -39.46 -37.575
    Goodwill, Net 106.225 106.287 106.285 106.251 106.069
    Intangibles, Net 4.274 7.242 10.21 13.178 16.145
    Other Long Term Assets, Total 2.316 2.512 2.255 2.531 2.374
    Total Current Liabilities 51.8 46.84 43.787 43.443 46.169
    Accounts Payable 7.327 6.089 6.109 7.914 9.305
    Accrued Expenses 24.602 20.853 19.072 19.01 21.053
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 14.871 15.315 15.273 14.436 14.978
    Total Liabilities 159.752 157.961 157.554 160.524 166.409
    Total Long Term Debt 59.59 60.662 61.734 62.809 63.885
    Long Term Debt 59.59 60.662 61.734 62.809 63.885
    Deferred Income Tax 1.017 1.049 1.052 1.055 0.62
    Other Liabilities, Total 47.345 49.41 50.981 53.217 55.735
    Total Equity 179.533 197.866 214.1 229.786 248.506
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.082 0.081 0.08 0.08 0.079
    Additional Paid-In Capital 856.926 853.466 850.063 847.008 845.034
    Retained Earnings (Accumulated Deficit) -980.976 -959.979 -942.939 -926.096 -905.251
    Unrealized Gain (Loss) -0.502 -0.949
    Other Equity, Total -1.949 -1.551 -1.328 -1.394 -1.66
    Total Liabilities & Shareholders’ Equity 339.285 355.827 371.654 390.31 414.915
    Total Common Shares Outstanding 79.47 79.121 78.652 79.482 79.246
    Current Port. of LT Debt/Capital Leases 5 4.583 3.333 2.083 0.833
    Short Term Investments 49.195 0 40.874 84.475 124.968
    Redeemable Preferred Stock 311.253 311.253 311.253 311.253 311.253
    Treasury Stock - Common -5.803 -5.404 -3.029 -0.563
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -190.098 -59.237 -53.02 -64.79 -59.013
    Cash From Operating Activities -89.37 -44.061 -15.417 -35.21 -25.201
    Cash From Operating Activities 3.499 3.653 4.014 4.605 5.372
    Amortization 11.528 11.918 11.91 11.2 11.2
    Non-Cash Items 101.183 19.538 19.265 27.014 19.718
    Cash Taxes Paid 0.309 2.085 0.521 0.205 0.321
    Cash Interest Paid 3.493 3.149 3.089 3.542 5.534
    Changes in Working Capital -15.482 -19.933 2.414 -13.239 -2.478
    Cash From Investing Activities -88.127 -11.946 39.975 -39.301 4.719
    Capital Expenditures -3.825 -13.264 -12.717 -2.531 -0.372
    Other Investing Cash Flow Items, Total -84.302 1.318 52.692 -36.77 5.091
    Cash From Financing Activities 230.758 15.959 20.857 2.79 57.66
    Financing Cash Flow Items -12.758 -1.872 -1.143 -2.517 -3.22
    Issuance (Retirement) of Stock, Net 225.354 1.494 22 2.133 60.88
    Foreign Exchange Effects -0.404 -0.021 0.385 0.056 0.167
    Net Change in Cash 52.857 -40.069 45.8 -71.665 37.345
    Issuance (Retirement) of Debt, Net 18.162 16.337 0 3.174
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -16.843 -190.098 -169.253 -139.827 -76.288
    Cash From Operating Activities -8.485 -89.37 -70.189 -45.578 -15.59
    Cash From Operating Activities 0.862 3.499 2.68 1.878 1.003
    Amortization 2.8 11.528 8.728 5.928 2.968
    Non-Cash Items 3.038 101.183 98.557 91.227 53.655
    Cash Taxes Paid 0.306 0.309 0.248 0.638 0.488
    Cash Interest Paid 0.232 3.493 1.847 1.679 0.102
    Changes in Working Capital 1.658 -15.482 -10.901 -4.784 3.072
    Cash From Investing Activities 43.154 -88.127 -128.372 -139.108 -0.868
    Capital Expenditures -1.01 -3.825 -3.07 -1.806 -0.868
    Other Investing Cash Flow Items, Total 44.164 -84.302 -125.302 -137.302 0
    Cash From Financing Activities -2.558 230.758 231.028 231.033 18.075
    Financing Cash Flow Items -12.758 -12.728 -12.724
    Issuance (Retirement) of Debt, Net 0 18.162 18.162 18.162 18.162
    Foreign Exchange Effects 0.023 -0.404 -0.719 -0.437 -0.085
    Net Change in Cash 32.134 52.857 31.748 45.91 1.532
    Issuance (Retirement) of Stock, Net -2.558 225.354 225.594 225.595 -0.087

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Standard BioTools Inc Company profile

    About Fluidigm Corporation

    Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.

    Equity composition

    Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.

    Industry: Advanced Medical Equipment & Technology (NEC)

    2 Tower Place
    Suite 2000
    SOUTH SAN FRANCISCO
    CALIFORNIA 94080
    US

    Income Statement

    • Annual
    • Quarterly

    News

    We’re partnering with Newsquawk

    Filter out the noise and focus on the news that matters.

    08:32, 23 April 2024

    US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

    The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

    15:56, 22 April 2024

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    People also watch

    ETH/USD

    3,222.23 Price
    +0.870% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    66,465.85 Price
    -0.220% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    US100

    17,560.50 Price
    +2.120% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Gold

    2,323.53 Price
    -0.140% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 21:00 (UTC)
    Spread 0.40

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading